ISRCTN19554893 https://doi.org/10.1186/ISRCTN19554893

Deferred registration: Quotient Sciences Code: QSC303849

Submission date 18/08/2026	**Recruitment status** Recruiting	[X] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [X] Record updated in last year
Registration date 18/08/2026	**Overall study status** Deferred	
Last Edited 18/08/2026	**Condition category** Other	

Plain English summary of protocol
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Contact information

Type(s)
Principal investigator

Contact name
Dr Litza McKenzie

Contact details
Mere Way, Ruddington Fields, Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)3303031000
recruitment@weneedyou.co.uk

Type(s)
Public, Scientific

Contact name
None Neurocrine Switzerland GmbH Study Doctor

Contact details
Switzerland Innovation Park Basel Area AG
Hegenheimermattweg 167A
Allschwil
Switzerland
4123

+359 887580697
Centermedinfo@neurocrine.com

Additional identifiers

Integrated Research Application System (IRAS)
1013719

Study information

Scientific Title
Deferred registration: Quotient Sciences Code: QSC303849 [Full scientific title to be added on or before the deferral expiry date]

Study objectives
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Ethics approval required
Ethics approval required

Ethics approval(s)
Submitted 19/06/2026, London Brent Research Ethics Committee (REC) (Health Research Authority 2 Redman Place Stratford, London, E20 1JQ, United Kingdom; +44 (0)2071048128; brent.rec@hra.nhs.uk), ref: 26/LO/0239

Primary study design
Interventional

Allocation
Non-randomized controlled trial

Masking
Open (masking not used)

Control
Active

Assignment
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Purpose
Phase I trial in healthy volunteers

Study type(s)

Health condition(s) or problem(s) studied
Healthy volunteers

Interventions
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Primary outcome(s)
1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Key secondary outcome(s)

Completion date
06/02/2027

Eligibility

Key inclusion criteria
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Healthy volunteers allowed
Yes

Age group
Adult

Lower age limit
18 Years

Upper age limit
55 Years

Sex
All

Total final enrolment
0

Key exclusion criteria

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Date of first enrolment
19/08/2026

Date of final enrolment
06/02/2027

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Quotient Sciences
Mere Way
Ruddington Fields
Ruddington
Nottingham
England
NG11 6JS

Sponsor information

Organisation
Neurocrine Switzerland GmbH

Funder(s)

Funder type

Funder Name
Neurocrine Switzerland GmbH

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available